Kim Kyeong Ok, Gluck Michael
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Clin Endosc. 2019 Mar;52(2):137-143. doi: 10.5946/ce.2019.009. Epub 2019 Mar 26.
Fecal microbiota transplantation (FMT) is an infusion in the colon, or the delivery through the upper gastrointestinal tract, of stool from a healthy donor to a recipient with a disease believed to be related to an unhealthy gut microbiome. FMT has been successfully used to treat recurrent Clostridium difficile infection (rCDI). The short-term success of FMT in rCDI has led to investigations of its application to other gastrointestinal disorders and extra-intestinal diseases with presumed gut dysbiosis. Despite the promising results of FMT in these conditions, several barriers remain, including determining the characteristics of a healthy microbiome, ensuring the safety of the recipient with respect to long-term outcomes, adequate monitoring of the recipient of fecal material, achieving high-quality control, and maintaining reasonable costs. For these reasons, establishing uniform protocols for stool preparation, finding the best modes of FMT administration, maintaining large databases of donors and recipients, and assuring that oral ingestion is equivalent to the more widely accepted colonoscopic infusion are issues that need to be addressed.
粪便微生物群移植(FMT)是将健康供体的粪便通过结肠输注或经上消化道输送到被认为与不健康肠道微生物群相关疾病的受体体内。FMT已成功用于治疗复发性艰难梭菌感染(rCDI)。FMT在rCDI中的短期成功促使人们研究其在其他胃肠道疾病和假定存在肠道生态失调的肠外疾病中的应用。尽管FMT在这些情况下取得了令人鼓舞的结果,但仍存在一些障碍,包括确定健康微生物群的特征、确保受体在长期预后方面的安全性、对粪便接受者进行充分监测、实现高质量控制以及维持合理成本。由于这些原因,制定统一的粪便制备方案、找到最佳的FMT给药方式、维护供体和受体的大型数据库以及确保口服与更广泛接受的结肠镜输注等效,都是需要解决的问题。